euro adhoc: Intercell AG / other / Development of the next generation Flu vaccines commenced - Phase I for Influenza vaccine adjuvanted with Intercell´s IC31TM started

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

18.06.2007

» Phase I clinical trial for a superior seasonal Influenza vaccine
formulated with IC31TM started

» The vaccine will be tested in three different dose groups - primary
endpoints of the study include safety and immunogenicity with a
strong focus on T-cell responses

» First results of the study are expected in early 2008

» Currently available vaccines are suboptimal, especially in
vulnerable risk groups (elderly and infants) - high market
potential for novel, adjuvanted vaccine products with broader
protection

Vienna (Austria), June 18, 2007 - Vaccine company Intercell AG (VSE:
ICLL) announced today the start of Phase I clinical trials for a
seasonal Flu vaccine which is formulated with Intercell´s proprietary
adjuvant IC31TM.

The currently available, mostly non-adjuvanted vaccine products have
a suboptimal efficacy profile, especially in the population groups
with the highest disease burden (elderly and infants). Furthermore,
these vaccines only offer limited cross-protection against other
influenza strains, with no or low T-cell responses. Due to these
limitations, novel vaccines with improved efficacy and T-cell
immunity are needed.

The IC31TM adjuvanted Flu vaccine is expected to overcome these
shortcomings, which would be also desired for pre-pandemic vaccines.

Preclinical animal models already showed that the vaccine could
increase Haemaglutinin titers and specific T-cell responses
significantly. Furthermore, the presence of IC31™ induces very
long-lasting and high levels of Flu-specific T-cells as well as
IgG2a, both markers for an immune response known to improve and
broaden protection from Influenza infections.

In this Phase I trial, a single dose of the IC31TM adjuvanted Flu
vaccine will be applied to healthy volunteers. Three different dose
groups (no IC31TM - low IC31TM - high IC31TM) will be tested. The
primary endpoints of the study comprise the safety and immunogenicity
of the vaccine at day 21.

"Both the encouraging preclinical data and the outstanding
immunogenicity profile in humans have opened a new and attractive
market for our adjuvant IC31TM in the development of vaccines. With
this study, an important development step for the next generation
Influenza vaccines has begun", stated Gerd Zettlmeissl, CEO of
Intercell.

About IC31TM

Adjuvants enhance the effectiveness of vaccines. Existing adjuvants
on the market induce antibodies but no or little T-cell immunity.
IC31TM is an adjuvant inducing both T-cell and B-cell responses with
a unique synthetic formulation, which combines the immunostimulating
properties of an anti-microbial peptide, KLK, and an
immunostimulatory oligodeoxynucleotide, ODN1a. The two-component
solution can simply be mixed with antigens: no conjugation is
required.

end of announcement euro adhoc 18.06.2007 17:58:28
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market